C García-López, V García-López… - International Journal of …, 2023 - mdpi.com
Ocular neurodegenerative diseases such as glaucoma, diabetic retinopathy, and age- related macular degeneration are common retinal diseases responsible for most of the …
AK Sahin, HB Kapti, A Uzun - International Journal of …, 2022 - ncbi.nlm.nih.gov
AIM To evaluate the short-term effects of oral citicoline therapy on the retinal nerve fiber layer (RNFL) and the macular ganglion cell-inner plexiform layer (mGCIPL) in patients with …
Glaucoma is a neurodegenerative disease characterized by the loss of retinal ganglion cells (RGCs), with intraocular pressure (IOP) being its primary risk factor. Despite controlling IOP …
JJ Secades, P Gareri - Revista de Neurologia, 2022 - ncbi.nlm.nih.gov
This review is based on the previous one published in 2016 (Secades JJ. Citicoline: pharmacological and clinical review, 2016 update. Rev Neurol 2016; 63 (Supl 3): S1-S73) …
SC DurCristiano - Current Molecular Medicine, 2023 - ingentaconnect.com
Glaucoma is a common cause of visual loss and irreversible blindness, affecting visual and life quality. Various mechanisms are involved in retinal ganglion cell (RGC) apoptosis and …
SC Durán-Cristiano - Revista mexicana de oftalmología, 2022 - scielo.org.mx
El sistema nervioso recibe y procesa la información proveniente del entorno, gracias a la constante interacción con órganos sensoriales, entre ellos la visión, el cual es considerado …
SC Durán-Cristiano - Revista mexicana de oftalmología, 2022 - scielo.org.mx
Actividad colinérgica y su papel en el sistema visual Cholinergic system and the role it plays in the visual system Page 1 82 Actividad colinérgica y su papel en el sistema visual Cholinergic …
JA Matamoros Felipe, S Rubio-Casado… - 2024 - docta.ucm.es
Glaucoma is a neurodegenerative disease characterized by the loss of retinal ganglion cells (RGCs), with intraocular pressure (IOP) being its primary risk factor. Despite controlling IOP …
JJ Secades, P Gareri - Revista de Neurología, 2022 - ncbi.nlm.nih.gov
Esta revisión se basa en la publicada en 2016–Secades JJ. Citicolina: revisión farmacológica y clínica, actualización 2016. Rev Neurol 2016; 63 (Supl 3): S1-S73–, e …